HK1207113A1 - Rnai pharmaceutical composition capable of suppressing expression of kras gene kras rnai - Google Patents

Rnai pharmaceutical composition capable of suppressing expression of kras gene kras rnai

Info

Publication number
HK1207113A1
HK1207113A1 HK15107660.7A HK15107660A HK1207113A1 HK 1207113 A1 HK1207113 A1 HK 1207113A1 HK 15107660 A HK15107660 A HK 15107660A HK 1207113 A1 HK1207113 A1 HK 1207113A1
Authority
HK
Hong Kong
Prior art keywords
rnai
kras
pharmaceutical composition
composition capable
suppressing expression
Prior art date
Application number
HK15107660.7A
Other languages
English (en)
Chinese (zh)
Inventor
直井智幸
窪山剛之
榎園淳
石井俊彥
德永昌浩
畑中劍太朗
Original Assignee
Kyowa Hakko Kirin Co Ltd
Dicerna Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd, Dicerna Pharmaceuticals Inc filed Critical Kyowa Hakko Kirin Co Ltd
Publication of HK1207113A1 publication Critical patent/HK1207113A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK15107660.7A 2012-07-16 2015-08-08 Rnai pharmaceutical composition capable of suppressing expression of kras gene kras rnai HK1207113A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261671963P 2012-07-16 2012-07-16
PCT/JP2013/069322 WO2014013995A1 (ja) 2012-07-16 2013-07-16 KRAS遺伝子発現抑制RNAi医薬組成物

Publications (1)

Publication Number Publication Date
HK1207113A1 true HK1207113A1 (en) 2016-01-22

Family

ID=49948821

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15107660.7A HK1207113A1 (en) 2012-07-16 2015-08-08 Rnai pharmaceutical composition capable of suppressing expression of kras gene kras rnai
HK15108285.0A HK1207666A1 (en) 2012-07-16 2015-08-26 Rnai pharmaceutical composition capable of suppressing expression of kras gene kras rnai

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15108285.0A HK1207666A1 (en) 2012-07-16 2015-08-26 Rnai pharmaceutical composition capable of suppressing expression of kras gene kras rnai

Country Status (10)

Country Link
US (1) US9913907B2 (ja)
EP (1) EP2873732A4 (ja)
JP (1) JP6272226B2 (ja)
CN (1) CN104471062A (ja)
AU (1) AU2013291125A1 (ja)
CA (1) CA2878314A1 (ja)
HK (2) HK1207113A1 (ja)
SG (1) SG11201502954TA (ja)
TW (1) TW201408324A (ja)
WO (1) WO2014013995A1 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2921573T3 (es) * 2009-04-03 2022-08-29 Dicerna Pharmaceuticals Inc Métodos y composiciones para la inhibición específica de KRAS por RNA bicatenario asimétrico
TW201625310A (zh) * 2014-06-04 2016-07-16 Kyowa Hakko Kirin Co Ltd ＣＫＡＰ５基因表現抑制ＲＮＡｉ醫藥組合物
CA2959358C (en) * 2014-06-30 2022-07-26 Kyowa Hakko Kirin Co., Ltd. Cationic lipid
WO2018102397A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
US20190351039A1 (en) 2017-02-01 2019-11-21 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
EP3617314B1 (en) * 2017-04-28 2023-02-15 Kyowa Kirin Co., Ltd. Oligonucleotide derivative or salt thereof
CN112118847B (zh) * 2018-03-02 2024-05-28 伊莱西奥治疗有限公司 包含突变kras序列和脂质的化合物及其用途
CN111534520A (zh) * 2020-05-27 2020-08-14 深圳市疾病预防控制中心（深圳市卫生检验中心、深圳市预防医学研究所） 特异抑制K-ras基因表达的慢病毒和重组载体构建及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1270198C (en) 1984-08-08 1990-06-12 Marcel B Bally ENCAPSULATION OF ANTINEOPLASTIC AGENTS IN LIPOSONES
ATE50983T1 (de) 1985-01-07 1990-03-15 Syntex Inc Oberflaechenaktive n-(omega, omega-1-dialkoxy)und n-(omega, omega-1-dialkenoxy)-alk-1-yl-n,n,ntrisubstituierte ammoniumverbindungen, deren herstellung und sie enthaltende pharmazeutische formulierungen.
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
JP2923296B2 (ja) * 1988-11-14 1999-07-26 株式会社ビタミン研究所 細胞への遺伝子導入法
JPH0696670B2 (ja) 1988-11-16 1994-11-30 日本ポリウレタン工業株式会社 反応性安定化ポリオール組成物
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6469158B1 (en) 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5977343A (en) 1992-05-14 1999-11-02 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5804683A (en) 1992-05-14 1998-09-08 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA with alkylamine
ES2186690T3 (es) 1993-09-02 2003-05-16 Ribozyme Pharm Inc Acido nucleico enzimatico que contiene no-nucleotidos.
US5889136A (en) 1995-06-09 1999-03-30 The Regents Of The University Of Colorado Orthoester protecting groups in RNA synthesis
CA2237316C (en) 1995-11-30 2012-06-26 Vical Incorporated Complex cationic lipids
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
CA2289702C (en) 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
WO1998058630A1 (en) 1997-06-23 1998-12-30 Sequus Pharmaceuticals, Inc. Liposome-entrapped polynucleotide composition and method
US6111086A (en) 1998-02-27 2000-08-29 Scaringe; Stephen A. Orthoester protecting groups
AU1830200A (en) * 1998-11-25 2000-06-13 Vanderbilt University Cationic liposomes for gene transfer
IL151928A0 (en) 2000-03-30 2003-04-10 Whitehead Biomedical Inst Rna sequence-specific mediators of rna interference
DE60141078D1 (de) 2000-10-04 2010-03-04 Kyowa Hakko Kirin Co Ltd Methode zur beschichtung feiner teilchen mit einem lipidfilm
US20020132788A1 (en) 2000-11-06 2002-09-19 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
PT2280070E (pt) 2001-07-23 2015-10-29 Univ Leland Stanford Junior Métodos e composições para inibição mediada por iarn da expressão génica em mamíferos
US7799565B2 (en) 2004-06-07 2010-09-21 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering RNA
KR20070104575A (ko) 2005-01-28 2007-10-26 교와 핫꼬 고교 가부시끼가이샤 표적 유전자의 발현을 억제하는 조성물
GB0505969D0 (en) 2005-03-23 2005-04-27 Novartis Ag Organic compounds
CA2679388A1 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting ras gene expression and uses thereof
CA3044134A1 (en) 2008-01-02 2009-07-09 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
CN102325534B (zh) * 2008-12-18 2016-02-17 戴瑟纳制药公司 延长的dicer酶底物和特异性抑制基因表达的方法
ES2921573T3 (es) * 2009-04-03 2022-08-29 Dicerna Pharmaceuticals Inc Métodos y composiciones para la inhibición específica de KRAS por RNA bicatenario asimétrico
JP5902616B2 (ja) * 2010-04-28 2016-04-13 協和発酵キリン株式会社 カチオン性脂質
US20140045913A1 (en) * 2011-12-12 2014-02-13 Kyowa Hakko Kirin Co., Ltd. Lipid nano particles comprising combination of cationic lipid
EP2792367A4 (en) 2011-12-12 2015-09-30 Kyowa Hakko Kirin Co Ltd LIPID NANOPARTICLES FOR A DRUG DELIVERY SYSTEM CONTAINING CATIONIC LIPIDS

Also Published As

Publication number Publication date
TW201408324A (zh) 2014-03-01
WO2014013995A1 (ja) 2014-01-23
EP2873732A1 (en) 2015-05-20
EP2873732A4 (en) 2016-03-23
CN104471062A (zh) 2015-03-25
JP6272226B2 (ja) 2018-01-31
CA2878314A1 (en) 2014-01-23
US9913907B2 (en) 2018-03-13
SG11201502954TA (en) 2015-05-28
AU2013291125A1 (en) 2015-01-22
US20140044755A1 (en) 2014-02-13
HK1207666A1 (en) 2016-02-05
JPWO2014013995A1 (ja) 2016-07-07

Similar Documents

Publication Publication Date Title
IL281295A (en) Preparations and methods for inhibiting expression of the ALAS1 gene
HK1204770A1 (en) Compartmentalized method of nucleic acid delivery and compositions and uses thereof
HK1211316A1 (en) Mirna modulators of thermogenesis mirna
EP2677865A4 (en) BROMODOMAIN INHIBITORS AS MODULATORS OF GENE EXPRESSION
EP2691121A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TMPRSS6 GENE
HK1207666A1 (en) Rnai pharmaceutical composition capable of suppressing expression of kras gene kras rnai
EP2855680A4 (en) COMPOSITIONS AND METHODS FOR SILENCING GENE EXPRESSION
HK1209621A1 (en) Inhibitors of the mir-15 family of micro-rnas mir-15 rna
EP2917314A4 (en) OLIGOMERATZUSAMMENSETZUNG
SI2691083T1 (sl) Farmacevtski sestavek sitagliptina
HRP20180567T1 (hr) Farmaceutski pripravak omeprazola
ZA201504442B (en) Regulation of gene expression
HK1214160A1 (zh) 抑制劑的藥物組合物
PT3524260T (pt) Composições farmacêuticas para o tratamento de inapetência
HK1201066A1 (en) Pyranopyridone inhibitors of tankyrase
ZA201402165B (en) Compositions of lopinavir
GB201100786D0 (en) Pharmaceutical compositions of immunosuppressants
EP2884964A4 (en) PHARMACEUTICAL COMPOSITION OF PROPOFOL
EP2739738A4 (en) USE OF INTEGRASE FOR TARGETED GENE EXPRESSION
IL233445A0 (en) Methods and preparations for gene transfer
IL233879A0 (en) Dry powdered dnase i preparations
GB201104632D0 (en) Use of medicament